Grupo Hospitalario Quirónsalud
|
Dr. Rafael Rosell
Medical director and president of the Instituto Oncológico. Hospital Universitari Dexeus · Grupo Quirónsalud
at
Grupo Hospitalario Quirónsalud
|
|
Speciality
|
Medical director and president of the Instituto Oncológico. Hospital Universitari Dexeus · Grupo Quirónsalud |
|
Languages
|
English, Spanish
|
|
About
|
Dr. Rosell is a specialist in medical oncology, with advanced training in lung cancer (non-small cell lung cancer). In 1982, he completed his residency at Memorial Sloan-Kettering Cancer Center, in New York, under Dr R. Gralla, Dept. of medicine (developmental chemotherapy).
Memberships in International scientific associations: European Society for Medical Oncology (ESMO). American Society of Clinical Oncology (ASCO). International Association for the Study of Lung Cancer (IASLC). European Organization for Research and Treatment of Cancer (EORTC). Spanish Lung Cancer Group (President, 1991-2014). No. of publications in first-quartile International journals , 3,200 total publications in the 1st quartile (over 40 years of practice). The 2 most important, for which Dr Rosell was the main author, are: “Erlotinib versus chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial” Lancet Oncology 2012 Mar;13(3):239-246. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554
No. of patents (participated in securing): 18. |
|
|